Cargando…
Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes a respiratory illness known as COVID-19. COVID-19 is a pandemic affecting many countries globally.(1) As of 23(rd) July 2020, there have been 297,146 lab-confirmed cases of COVID-19 in t...
Autores principales: | Cranmer, Holly, Podkonjak, Tanja, Benson, Eugene, Dabora, Jonathon, Jackson, Graham H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330250/ http://dx.doi.org/10.1182/blood-2020-142338 |
Ejemplares similares
-
Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020) -
Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
por: Neparidze, Natalia, et al.
Publicado: (2021) -
Utilizing HealthTree ® Cure Hub's Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 Pandemic
por: Sweeney, Nathan W., et al.
Publicado: (2021) -
COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021) -
COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study
por: Ip, Andrew, et al.
Publicado: (2020)